Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
To read the full story
Related Article
- US FDA Grants Orphan Exclusivity for ALS Drug Radicava ORS
April 10, 2024
- Oral Radicava Approved in Switzerland: Mitsubishi Tanabe
May 12, 2023
- Canada Approves Mitsubishi Tanabe’s Oral Edaravone for ALS
November 10, 2022
- US FDA OKs Mitsubishi Tanabe’s Oral Edaravone for ALS
May 16, 2022
- Mitsubishi Tanabe’s Oral Edaravone Filed in Japan for ALS
March 15, 2022
- Mitsubishi Tanabe’s Oral Edaravone Accepted for FDA Review in ALS
January 14, 2022
BUSINESS
- Sumitomo Sets Out for Reconstruction, Further Cost Cuts in FY2024
May 2, 2024
- Sumitomo’s FY2023 Operating Loss Outlook Swells to 354.9 Billion Yen
May 2, 2024
- Konica Minolta Divests Invicro in Precision Business Rejig
May 2, 2024
- Regeneron Set for Commercial Expansion in Japan, Eyes Dupixent Ramp-Up
May 1, 2024
- Ono Picks Up Deciphera in US$2.4 Billion Deal to Extend Pipeline, Market Channels
May 1, 2024
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…